SecBot SecBot
PRESS-RELEASE ·Filed Mar 30, 2026

RPRX

Royalty Pharma plc
NEUTRAL
Impact 4/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Contract
Actionable Insight • Neutral

Monitor clinical trial progress of JNJ-4804; success could enhance Royalty Pharma’s future royalty portfolio, but near-term financials will reflect cash outflows. Given recent insider selling, assess whether this capital deployment aligns with shareholder priorities.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$46.37
T+0 close · Mar 30, 2026 · via day close
Latest settled
+17.94%
T+60 · $54.69
Vs SPY
+1.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $46.37entry
  2. T+1 · 8mo ago +3.45%α +0.56% · $47.97
  3. T+5 · 7mo ago +1.08%α −3.22% · $46.87
  4. T+20 · 7mo ago +6.84%α −5.76% · $49.54
  5. T+60 · 5mo ago +17.94%α +1.45% · $54.69
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Royalty Pharma announced a $500 million R&D co-funding agreement with Johnson & Johnson to advance JNJ-4804, an investigational dual-pathway inhibitor for autoimmune diseases. The deal reflects Royalty Pharma's strategy of funding late-stage innovation in immunology, but carries development-stage risk with no near-term revenue impact. This is a non-dilutive use of capital that could yield future royalty streams if the therapy succeeds.

Key Financial Metrics

Deal Value
$500.0M

Key Facts

  • Royalty Pharma and Johnson & Johnson entered a $500 million co-funding agreement for JNJ-4804 development in 2026–2027
  • JNJ-4804 is a novel co-antibody therapy targeting IL-23 and TNF pathways for chronic immune-mediated diseases
  • The collaboration builds on Royalty Pharma's immunology investment strategy and existing royalty relationship with J&J (Tremfya)
  • No equity exchange or ownership stake mentioned, structured as a development funding partnership
  • Goodwin Procter served as legal advisor to Royalty Pharma

Financial Impact

$500 million in R&D funding over 2026–2027

cash flowfuture royalty revenueR&D investment

Risk Factors

  • Clinical development risk, JNJ-4804 may fail in trials or not gain regulatory approval
  • No guaranteed return; potential returns depend entirely on commercial success of the therapy
  • Capital could have been returned to shareholders via buybacks or dividends

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3264509

Track record

23 reports on RPRX

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +15.20% at T+60 after the May 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry price pending
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $67.57 to $68.97 Now $69.31 +2.58% ▲ +2.07% −1.22% vs SPY
  3. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  4. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $67.56 to $70.01 Now $69.31 +2.59% ▲ +3.63% +4.54% vs SPY
  5. Sep 30, 20266w ago Insider Cluster Bearish 5/10 Entry $57.63 to $56.21 Now $69.31 −20.27% ▲ +2.46% +3.77% vs SPY
  6. Sep 4, 202610w ago Press Release Bearish 5/10 Entry $60.59 to $58.47 Now $69.31 −14.39% ▲ +3.50% +2.38% vs SPY
  7. Aug 19, 202612w ago Insider Cluster Neutral 3/10 Entry $60.57 to $61.92 Now $69.31 +14.44% ▲ +2.24% +1.12% vs SPY
  8. Aug 12, 202613w ago 144 Neutral 3/10 Entry $58.56 to $60.58 Now $69.31 +18.36% ▲ +3.45% +5.41% vs SPY
  9. Aug 5, 202614w ago 8-K Bullish 6/10 Entry $57.75 to $59.22 Now $69.31 +20.02% ▲ +2.55% +2.19% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Neutral 2/10 Entry $57.77 to $57.96 Now $69.31 +19.98% ▲ +0.33% −0.60% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (12h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 30, 2026